Secondary consent to biospecimen use in a prostate cancer biorepository

Bettina F. Drake, Katherine Brown, Lucy D.Agostino McGowan, Jennifer Haslag-Minoff, Kimberly Kaphingst

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Background: Biorepository research has substantial societal benefits. This is one of the few studies to focus on male willingness to allow future research use of biospecimens. Methods: This study analyzed the future research consent questions from a prostate cancer biorepository study (N = 1931). The consent form asked two questions regarding use of samples in future studies (1) without and (2) with protected health information (PHI). Yes to both questions of use of samples was categorized as Yes-Always; Yes to without and No to with PHI was categorized as Yes-Conditional; No to without PHI was categorized as Never. We analyzed this outcome to determine significant predictors for consent to Yes-Always vs. Yes-Conditional. Results: 99.33 % consented to future use of samples; 88.19 % consented to future use without PHI, and among those men 10.2 % consented to future use with PHI. Comparing Yes Always and Yes Conditional responses, bivariate analyses showed that race, family history, stage of cancer, and grade of cancer (Gleason), were significant at the α = 0.05 level. Using stepwise multivariable logistic regression, we found that African-American men were significantly more likely to respond Yes Always when compared to White men (p < 0.001). Those with a family history of prostate cancer were significantly more likely to respond Yes Always (p = 0.002). Conclusions: There is general willingness to consent to future use of specimens without PHI among men.

Original languageEnglish
Article number346
JournalBMC Research Notes
Volume9
Issue number1
DOIs
StatePublished - Jul 18 2016

Keywords

  • African-American
  • Biorepository
  • Consent
  • Prostate cancer
  • Protected health information

Fingerprint

Dive into the research topics of 'Secondary consent to biospecimen use in a prostate cancer biorepository'. Together they form a unique fingerprint.

Cite this